HUTCHMED (China) Limited (AIM: HCM)
Health Care · Pharmaceuticals · HK
£2.22
+0.45% today · -7.1% 1Y
HUTCHMED (China) Limited (AIM: HCM) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.55B.
Over the last twelve months the share price has lost 7.1%, trading between 1.50 and 2.46.
Tweenvest scores HUTCHMED (China) Limited across four factors: quality 57/100, value 55/100, growth 66/100. Its strongest factor is growth.
HCM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.55B
- Revenue (TTM)
- $549.12M
- P/E
- 145.89
- EPS
- 0.02
- Dividend yield
- —
- Beta (5Y)
- 0.36
- 52-week high
- £2.46
- 52-week low
- £1.50
- Avg volume (3M)
- —
- Shares outstanding
- 869.07M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Kangmei Pharmaceutical Co., Ltd.SHSE: 600518 | $2.76B | CN¥1.34 | +0.75% |
| Piramal Pharma LimitedNSEI: PPLPHARMA | $2.73B | Rs197.97 | -5.87% |
| Acutaas Chemicals LimitedNSEI: ACUTAAS | $2.72B | Rs3,196.50 | -2.32% |
| Curaleaf Holdings, Inc.TSX: CURA | $2.64B | CA$13.50 | -5.00% |
| China Resources Double-Crane Pharmaceutical Co.,Ltd.SHSE: 600062 | $2.50B | CN¥16.24 | +1.18% |
| Supernus Pharmaceuticals, Inc.NasdaqGM: SUPN | $2.46B | $42.14 | -0.57% |
| Almirall, S.A.BME: ALM | $2.45B | €10.06 | -1.95% |
| Liquidia CorporationNasdaqCM: LQDA | $2.39B | $28.02 | +5.02% |
Figures last refreshed Oct 4, 2026.